Compare ARL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | TRDA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7M | 274.5M |
| IPO Year | 1999 | 2021 |
| Metric | ARL | TRDA |
|---|---|---|
| Price | $21.12 | $7.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 11.6K | ★ 287.3K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,014,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $50.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.70 | N/A |
| 52 Week Low | $12.42 | $4.93 |
| 52 Week High | $24.44 | $16.45 |
| Indicator | ARL | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 53.92 |
| Support Level | $14.97 | $5.75 |
| Resistance Level | N/A | $10.82 |
| Average True Range (ATR) | 1.10 | 0.50 |
| MACD | 0.68 | 0.23 |
| Stochastic Oscillator | 67.14 | 80.10 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.